Harvard Bioscience Inc Total Assets
Harvard Bioscience Inc total assets. Based on the latest financial reports, Harvard Bioscience Inc (HBIO) holds total assets worth $76.29 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Harvard Bioscience Inc (HBIO) total market value for the company's overall valuation and market capitalisation.
Total Assets of Harvard Bioscience Inc (1998–2025)
Total assets of Harvard Bioscience Inc from 1998 to 2025. This chart illustrates how Harvard Bioscience Inc's total assets have evolved over time, based on quarterly financial data. See Harvard Bioscience Inc share price for real-time trading data and today's change.
Harvard Bioscience Inc - Asset Composition Analysis
Harvard Bioscience Inc Total Assets Breakdown (December 2025)
Harvard Bioscience Inc total assets breakdown as of December 2025. Harvard Bioscience Inc's total assets of $76.29 Million consist of 60.2% current assets and 39.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.8% |
| Accounts Receivable | $16.04 Million | 20.0% |
| Inventory | $20.80 Million | 26.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.64 Million | 9.5% |
| Goodwill | $9.56 Million | 11.9% |
Asset Composition Trend (1998–2025)
This chart illustrates how Harvard Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Harvard Bioscience Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harvard Bioscience Inc's current assets represent 60.2% of total assets in 2025, an increase from 13.3% in 1998.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2025, down from 13.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 26.0% of total assets.
Harvard Bioscience Inc Competitors by Total Assets
Key competitors of Harvard Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$1.15 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$2.77 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Harvard Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 0.81 | 2.37 |
| Quick Ratio | 0.98 | 0.41 | 1.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.67 Million | $-10.23 Million | $32.18 Million |
Harvard Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Harvard Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.00 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -36.8% |
| Total Assets | $80.07 Million |
| Market Capitalization | $36.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Harvard Bioscience Inc's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Harvard Bioscience Inc's assets decreased by 36.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Harvard Bioscience Inc (1998–2025)
The table below shows the annual total assets of Harvard Bioscience Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $80.07 Million | -36.77% |
| 2024-12-31 | $126.64 Million | -7.81% |
| 2023-12-31 | $137.37 Million | -5.50% |
| 2022-12-31 | $145.36 Million | -10.46% |
| 2021-12-31 | $162.34 Million | +3.90% |
| 2020-12-31 | $156.25 Million | -5.23% |
| 2019-12-31 | $164.87 Million | -1.91% |
| 2018-12-31 | $168.07 Million | +53.70% |
| 2017-12-31 | $109.35 Million | +1.47% |
| 2016-12-31 | $107.77 Million | -10.36% |
| 2015-12-31 | $120.22 Million | -11.55% |
| 2014-12-31 | $135.92 Million | +0.34% |
| 2013-12-31 | $135.46 Million | +1.48% |
| 2012-12-31 | $133.48 Million | +5.41% |
| 2011-12-31 | $126.63 Million | +1.47% |
| 2010-12-31 | $124.80 Million | +16.38% |
| 2009-12-31 | $107.23 Million | +31.94% |
| 2008-12-31 | $81.27 Million | -17.79% |
| 2007-12-31 | $98.85 Million | +6.03% |
| 2006-12-31 | $93.23 Million | +1.30% |
| 2005-12-31 | $92.03 Million | -34.20% |
| 2004-12-31 | $139.88 Million | +8.92% |
| 2003-12-31 | $128.43 Million | +19.38% |
| 2002-12-31 | $107.58 Million | +30.62% |
| 2001-12-31 | $82.36 Million | +40.05% |
| 2000-12-31 | $58.81 Million | +185.34% |
| 1999-12-31 | $20.61 Million | +185.46% |
| 1998-12-31 | $7.22 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more